Vaccination of allogeneic hematopoietic stem cell transplant recipients-what should be considered?

about

Vaccination of allogeneic hematopoietic stem cell transplant recipients-what should be considered?

Item

http://www.wikidata.org/entity/Q48342532

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Vaccination of allogeneic hema ...... nts-what should be considered?

@en

Vaccination of allogeneic hema ...... nts-what should be considered?

@nl

type

Item

label

Vaccination of allogeneic hema ...... nts-what should be considered?

@en

Vaccination of allogeneic hema ...... nts-what should be considered?

@nl

prefLabel

Vaccination of allogeneic hema ...... nts-what should be considered?

@en

Vaccination of allogeneic hema ...... nts-what should be considered?

@nl

P1476

Vaccination of allogeneic hema ...... nts-what should be considered?

@en

P2093

Anita Lawitschka

http://www.w3.org/2001/XMLSchema#string

Daniel Wolff

http://www.w3.org/2001/XMLSchema#string

Hildegard Greinix

http://www.w3.org/2001/XMLSchema#string

Jörg Halter

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and immunogenicity of the tetravalent protein-conjugated meningococcal vaccine (MCV4) in recipients of related and unrelated allogeneic hematopoietic stem cell transplantation.

Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study.

Pneumococcal conjugate and plain polysaccharide vaccines have divergent effects on antigen-specific B cells

Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016.

Vaccination of allogeneic haematopoietic stem cell transplant recipients: report from the international consensus conference on clinical practice in chronic GVHD.

Long-term persistence of the immune response to antipneumococcal vaccines after Allo-SCT: 10-year follow-up of the EBMT-IDWP01 trial.

Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation.

Randomized study of early versus late immunization with pneumococcal conjugate vaccine after allogeneic stem cell transplantation.

P304

701-702

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-017-2922-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Inken Hilgendorf

P577

2017-01-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28097373

http://www.w3.org/2001/XMLSchema#string